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469 Survival benefit of lung transplantation for patients with idiopathic
pulmonary fibrosis
Gabriel Thabut, MD, Herve´ Mal, MD, Yves Castier, MD, Odile Groussard, MD,
Olivier Brugie`re, MD, Rolana Marrash-Chahla, MD, Guy Lese`che, MD, and Michel Fournier,
MD, Clichy, France
Survival benefit offered by lung transplantation was assessed among 46 patients placed on a
waiting list with a diagnosis of IPF. By use of Cox regression modeling, lung transplantation
was found to be associated with a 75% reduction of the risk of death after adjustment on
potential confounding variables.
476 Living-donor lobar lung transplantation for various lung diseases
Hiroshi Date, MD, Motoi Aoe, MD, Itaru Nagahiro, MD, Yoshifumi Sano, MD,
Akio Andou, MD, Hiromi Matsubara, MD, Keiji Goto, MD, Takeo Tedoriya, MD, and
Nobuyoshi Shimizu, MD, Okayama, Japan
Living-donor lobar lung transplantation was performed in 14 patients with various lung diseases
including restrictive, obstructive, septic, and hypertensive lung diseases. All the patients are
currently alive with a follow-up period of 4 to 45 months. This type of procedure can be an
alternative to conventional cadaveric lung transplantation for both pediatric and adult patients.
482 Simvastatin ameliorates injury in an experimental model of lung ischemia-
reperfusion
Babu V. Naidu, FRCS, Steven M. Woolley, MRCS, Alexander S. Farivar, MD,
Robert Thomas, BA, Charles Fraga, MSc, and Michael S. Mulligan, MD, FACS, Seattle, Wash
Simvastatin possesses anti-inflammatory and antioxidant properties. Administration in a rat
model of lung ischemia-reperfusion is protective.
Surgery for Congenital
Heart Disease
(CHD)
490 Use of bovine jugular vein to reconstruct the right ventricular outflow tract:
Early results
Younes Boudjemline, MD, Damien Bonnet, MD, Tony Abdel Massih, MD,
Gabriella Agnoletti, MD, Franck Iserin, MD, Francis Jaubert, MD, Daniel Sidi, MD,
and Pascal Vouhe´, MD, Paris, France
We studied 28 consecutive patients who had undergone an RVOT reconstruction with the
implantation of a bovine jugular vein conduit and report their outcome within the first 3 months
after insertion. Follow-up demonstrates good valvar function in 87% of survivors. Two
thromboses and 3 reoperations for conduit aneurysm occurred.
498 Depopulated vena caval homograft: A new venous conduit
Winfield Wells, MD, Mahmoud Malas, MD, Craig J. Baker, MD, Susanne M. Quardt, MD, and
Mark L. Barr, MD, Los Angeles, Calif
Decellularized, cryopreserved vena caval homografts have been used to replace the SVC in a
large-animal model. After 6 months, these grafts have been repopulated by functioning cells
and show no evidence of degeneration or obstruction.
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